Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study-Reference-Cited by-同舟云学术

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Published:2016-04 Issue:4 Volume:3 Page:e196-e204
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Amorim Sandy,Stathis Anastasios,Gleeson Mary,Iyengar Sunil,Magarotto Valeria,Leleu Xavier,Morschhauser Franck,Karlin Lionel,Broussais Florence,Rezai Keyvan,Herait Patrice,Kahatt Carmen,Lokiec François,Salles Gilles,Facon Thierry,Palumbo Antonio,Cunningham David,Zucca Emanuele,Thieblemont Catherine

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Targeting bromodomains: epigenetic readers of lysine acetylation;Filippakopoulos;Nat Rev Drug Discov,2014

2. Selective inhibition of tumor oncogenes by disruption of super-enhancers;Lovén;Cell,2013

3. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma;Chapuy;Cancer Cell,2013

4. Selective inhibition of BET bromodomains;Filippakopoulos;Nature,2010

5. Development of the BET bromodomain inhibitor OTX015;Noel;Mol Cancer Ther,2013

Cited by 350 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple‐negative breast cancer (TNBC) cells;Cell Proliferation;2024-09-02

2. BRD4: an effective target for organ fibrosis;Biomarker Research;2024-08-30

3. Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity;Blood Cancer Journal;2024-08-19

4. BET inhibition revealed varying MYC addiction mechanisms independent of gene alterations in aggressive B-cell lymphomas.;2024-07-22

5. Next-Generation Therapies for Multiple Myeloma;Annual Review of Cancer Biology;2024-06-12